4.43
+0.09(+2.07%)
Currency In USD
| Previous Close | 4.34 |
| Open | 4.3 |
| Day High | 4.43 |
| Day Low | 4.25 |
| 52-Week High | 6.18 |
| 52-Week Low | 2.37 |
| Volume | 652,042 |
| Average Volume | 1.1M |
| Market Cap | 566.44M |
| PE | -40.27 |
| EPS | -0.11 |
| Moving Average 50 Days | 5.05 |
| Moving Average 200 Days | 4.11 |
| Change | 0.09 |
If you invested $1000 in Cytek Biosciences, Inc. (CTKB) since IPO date, it would be worth $236.14 as of February 21, 2026 at a share price of $4.43. Whereas If you bought $1000 worth of Cytek Biosciences, Inc. (CTKB) shares 3 years ago, it would be worth $403.83 as of February 21, 2026 at a share price of $4.43.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Cytek Biosciences to participate at the TD Cowen 46th Annual Health Care Conference
GlobeNewswire Inc.
Feb 18, 2026 9:05 PM GMT
FREMONT, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced the company will be participating in the upcoming TD Cowen 46th Annual Health Care Conference in B
Cytek Biosciences to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
GlobeNewswire Inc.
Feb 12, 2026 9:05 PM GMT
FREMONT, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), today announced it will report financial results for the fourth quarter and full year 2025 after market close on Thursday, F
Cytek Biosciences Announces Preliminary Fourth Quarter and Full Year 2025 Revenue Results
GlobeNewswire Inc.
Jan 12, 2026 10:00 AM GMT
Company to present at the 44th Annual JP Morgan Healthcare ConferenceFREMONT, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced preliminary, unaudited revenu